TY - JOUR
T1 - Sarcopenia and Cardiovascular Diseases
AU - Damluji, Abdulla A.
AU - Alfaraidhy, Maha
AU - AlHajri, Noora
AU - Rohant, Namit N.
AU - Kumar, Manish
AU - Al Malouf, Christina
AU - Bahrainy, Samira
AU - Kwak, Min Ji
AU - Batchelor, Wayne B.
AU - Forman, Daniel E.
AU - Rich, Michael W.
AU - Kirkpatrick, James
AU - Krishnaswami, Ashok
AU - Alexander, Karen P.
AU - Gerstenblith, Gary
AU - Cawthon, Peggy
AU - deFilippi, Christopher R.
AU - Goyal, Parag
N1 - Publisher Copyright:
© 2023 The Authors.
PY - 2023/5/16
Y1 - 2023/5/16
N2 - Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by chronic comorbidities including cardiovascular diseases, chronic kidney disease, and cancer. Sarcopenia is associated with faster progression of cardiovascular diseases and higher risk of mortality, falls, and reduced quality of life, particularly among older adults. Although the pathophysiologic mechanisms are complex, the broad underlying cause of sarcopenia includes an imbalance between anabolic and catabolic muscle homeostasis with or without neuronal degeneration. The intrinsic molecular mechanisms of aging, chronic illness, malnutrition, and immobility are associated with the development of sarcopenia. Screening and testing for sarcopenia may be particularly important among those with chronic disease states. Early recognition of sarcopenia is important because it can provide an opportunity for interventions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascular outcomes. Relying on body mass index is not useful for screening because many patients will have sarcopenic obesity, a particularly important phenotype among older cardiac patients. In this review, we aimed to: (1) provide a definition of sarcopenia within the context of muscle wasting disorders; (2) summarize the associations between sarcopenia and different cardiovascular diseases; (3) highlight an approach for a diagnostic evaluation; (4) discuss management strategies for sarcopenia; and (5) outline key gaps in knowledge with implications for the future of the field.
AB - Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by chronic comorbidities including cardiovascular diseases, chronic kidney disease, and cancer. Sarcopenia is associated with faster progression of cardiovascular diseases and higher risk of mortality, falls, and reduced quality of life, particularly among older adults. Although the pathophysiologic mechanisms are complex, the broad underlying cause of sarcopenia includes an imbalance between anabolic and catabolic muscle homeostasis with or without neuronal degeneration. The intrinsic molecular mechanisms of aging, chronic illness, malnutrition, and immobility are associated with the development of sarcopenia. Screening and testing for sarcopenia may be particularly important among those with chronic disease states. Early recognition of sarcopenia is important because it can provide an opportunity for interventions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascular outcomes. Relying on body mass index is not useful for screening because many patients will have sarcopenic obesity, a particularly important phenotype among older cardiac patients. In this review, we aimed to: (1) provide a definition of sarcopenia within the context of muscle wasting disorders; (2) summarize the associations between sarcopenia and different cardiovascular diseases; (3) highlight an approach for a diagnostic evaluation; (4) discuss management strategies for sarcopenia; and (5) outline key gaps in knowledge with implications for the future of the field.
KW - body mass index
KW - cardiovascular diseases
KW - older adults
KW - sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85159455444&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.123.064071
DO - 10.1161/CIRCULATIONAHA.123.064071
M3 - Review article
C2 - 37186680
AN - SCOPUS:85159455444
SN - 0009-7322
VL - 147
SP - 1534
EP - 1553
JO - Circulation
JF - Circulation
IS - 20
ER -